| Literature DB >> 31591421 |
Yun Zhang1, Dongmei Wang2, Yue Yin1, Yu Wang1, Hongwei Fan3, Wen Zhang4, Xuejun Zeng5.
Abstract
Giant cell arteritis (GCA) is a medium- and large-vessel vasculitis with an onset age after 50 years. Takayasu arteritis (TA), which is also a large-vessel vasculitis with an onset age earlier than 40 years, was suggested to be associated with tuberculosis (TB). However, the association between GCA and TB was rarely reported. This study was to retrospectively analyze clinical data of GCA patients at Peking Union Medical College Hospital and elucidate the association between GCA and TB. Ninety-one patients diagnosed with GCA were included in the study. A total of 20 patients (22.0%) had a history of active tuberculosis and received anti-tuberculosis therapy. On comparing the clinical features of patients with GCA and concomitant TB and those without TB, obvious weight loss (P = 0.011), lower percentage of dyslipidemia (P = 0.042), higher percentage of anti-phospholipid antibodies (P = 0.010), and lower white blood cells (P = 0.006) were noted in the TB group. In conclusion, this study demonstrated the percentage of TB history in patients with GCA was higher than that in the Chinese general population. Clinicians should recognize the possibility of comorbid TB in patients with obvious weight loss and relatively lower white blood cell count.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31591421 PMCID: PMC6779871 DOI: 10.1038/s41598-019-50892-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinical features and comorbid diseases of the patients with TB and without TB.
| GCA with TB | GCA without TB | ||
|---|---|---|---|
|
| |||
| Age (years, diagnosis) | 65.10 ± 8.39 | 65.38 ± 7.51 | 0.886 |
| Disease course (months) | 5.35 ± 5.59 | 9.71 ± 19.31 | 0.322 |
| Sex | |||
| Male | 6 (30) | 35 (49.3) | 0.126 |
| Female | 14 (70) | 36 (50.7) | |
|
| |||
| Headache | 6 (30) | 21 (29.6) | 0.971 |
| Fever | 16 (80) | 58 (81.7) | 0.864 |
| Scalp tenderness or pain | 2 (10) | 22 (31.0) | 0.060 |
| Tenderness and abnormal pulsation of temporal artery | 6 (30) | 13 (18.3) | 0.256 |
| Visual loss | 8 (40) | 25 (35.2) | 0.694 |
| Myalgia | 12 (60) | 39 (54.9) | 0.687 |
| CNS symptoms | (25) | 16 (22.5) | 0.817 |
| Hearing loss | 3 (15) | 20 (28.2) | 0.231 |
| Jaw claudication | 6 (30) | 20 (28.2) | 0.873 |
| Arthralgia | 11 (55) | 36 (50.7) | 0.734 |
| GI symptoms | 1 (5) | 11 (15.5) | 0.221 |
| Constitutional symptoms | 14 (70) | 47 (66.2) | 0.749 |
| Weight loss* | 16 (80) | 34 (47.9) |
|
|
| |||
| Atherosclerosis | 4 (20) | 28 (39.4) | 0.108 |
| Smoking | 6 (30) | 27 (38.0) | 0.509 |
| Diabetes | 1 (5) | 13 (18.3) | 0.145 |
| Cerebrovascular disease | 2 (10) | 6 (8.5) | 0.829 |
| Coronary artery disease | 2 (10) | 11 (15.5) | 0.535 |
| Hypertension | 9 (45) | 23 (32.4) | 0.297 |
| Dyslipidemia* | 3 (15) | 28 (39.4) |
|
CNS symptoms: vertigo, transient ischemia attack, and stroke; GI in volvement: abdominal pain and abdominal distention; constitutional symptom: fatigue, night sweat, and anorexia.
CNS, Central nervous system; GCA, giant cell arteritis; GI, gastrointestinal; TB, tuberculosis.
*Significantly different.
Laboratory findings and follow-up results of GCA patients according to TB.
| GCA with TB | GCA without TB | ||||||
|---|---|---|---|---|---|---|---|
| Mean ± SD (range) | Total | Mean ± SD (range) | Total | ||||
|
| |||||||
| ESR (mm/h) | 94.50 ± 28.21 (44−140) | 20 | 90.01 ± 27.74 (21−140) | 71 | 0.526 | ||
| CRP (mg/L) | 76.71 ± 59.67 (2.47−197) | 20 | 80.68 ± 63.45 (1.8−275.66) | 71 | 0.803 | ||
| ALB (g/L) | 33.20 ± 5.65 (24−47) | 20 | 32.38 ± 4.30 (22−42) | 69 | 0.486 | ||
| WBC ( × 109/L) * | 6.92 ± 2.39 (1.47−10.91) | 20 | 9.80 ± 4.42 (2.36−26.60) | 69 |
| ||
| Leukopenia | 3 (15) | 20 | 3 (4.3) | 69 | 0.148 | ||
| LYM ( × 109/L) | 1.65 ± 0.67 (0.62−2.94) | 20 | 1.63 ± 0.78 (0.40−4.20) | 69 | 0.914 | ||
| HGB (g/L) | 100.30 ± 17.14 (63−132) | 20 | 108.84 ± 19.86 (63−146) | 69 | 0.085 | ||
| PLT ( × 109/L) | 400.20 ± 151.07 (130−653) | 20 | 373.75 ± 152.83 (99−725) | 69 | 0.496 | ||
| Fbg (g/L) | 6.25 ± 2.69 (2.90−10.00) | 20 | 5.30 ± 2.12 (2.00−10.49) | 57 | 0.100 | ||
| ANA positive | 6 (30) | 20 | 12 (17.6) | 68 | 0.229 | ||
| ANCA positive | 1 (5) | 20 | 12 (18.8) | 64 | 0.138 | ||
| APS positive* | 5 (55.6) | 9 | 5 (14.7) | 34 |
| ||
| 4 LA + 1 ACL+ | 4 ACL + 1 β 2GP1 + 1 positive for 3 antibodies | ||||||
| Elevated RF | 2 (15.4) | 13 | 17 (33.3) | 51 | 0.206 | ||
| Elevated IgG* | 7 (50) | 14 | 14 (23.3) | 60 |
| ||
|
| |||||||
| Non-relapsing | 11 (64.7) | 17 | 26 (43.3) | 60 | 0.119 | ||
| Relapsing | 2 (11.8) | 17 | 24 (40) | 60 |
| ||
| Comorbid with tumors | 1 (5.9) | 17 | 1 (1.7) | 60 | 0.335 | ||
| Death | 3 (17.6) | 17 | 9 (15) | 60 | 0.791 | ||
ALB, Albumin; ACL, anti-cardiolipin antibody; ANA, anti-nuclear antibody; ANCA, anti-neutrophil cytoplasmic antibody; APS, anti-phospholipid antibody; β 2GP1, β2glycoprotein1; CRP, C-reactive protein; ESR, erythrocyte sedition rate; Fbg, fibrinogen; GCA, giant cell arteritis HGB, hemoglobin; Ig G, immunoglobin G; LA, lupus anticoagulant; LYM, lymphocyte; PLT, platelet; RF, rheumatic factor; SD, standard deviation; TB, tuberculosis; WBC, white blood cell. *Significantly different.